Log in to save to my catalogue

Multimodal decoding of human liver regeneration

Multimodal decoding of human liver regeneration

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2779803111

Publication information

Publisher

Cold Spring Harbor: Cold Spring Harbor Laboratory Press

More information

Scope and Contents

Contents

The liver has a unique ability to regenerate however in the setting of acute liver failure (ALF) this regenerative capacity is often overwhelmed and emergency liver transplantation is the only curative option. To advance our understanding of human liver regeneration and to inform design of pro-regenerative therapies, we use paired single-nuclei RNA sequencing (snRNAseq)combined with spatial profiling of healthy and ALF explant human livers to generate the first single-cell, pan-lineage atlas of human liver regeneration. We uncover a novel ANXA2+ migratory hepatocyte subpopulation which emerges during human liver regeneration, and a corollary migratory hepatocyte subpopulation in a mouse model of acetaminophen (APAP)-induced liver regeneration. Importantly, interrogation of necrotic wound closure and hepatocyte proliferation across multiple timepoints following APAP-induced liver injury in mice demonstrates that wound closure precedes hepatocyte proliferation. 4-D intravital imaging of APAP-induced mouse liver injury identifies motile hepatocytes at the edge of the necrotic area, enabling collective migration of the hepatocyte sheet to effect wound closure. Depletion of hepatocyte ANXA2 expression reduces HGF-induced human and mouse hepatocyte migration in vitro, and abrogates necrotic wound closure following APAP-induced mouse liver injury. Taken together, our work dissects unanticipated aspects of liver regeneration, demonstrating an uncoupling of wound closure and hepatocyte proliferation and uncovering a novel migratory hepatocyte subpopulation which mediates wound closure following liver injury. Therapies designed to promote rapid reconstitution of normal hepatic microarchitecture and reparation of the gut-liver barrier may open up new areas of therapeutic discovery in regenerative medicine.Competing Interest StatementN.C.H. has received research funding from AbbVie, Pfizer, Gilead, Boehringer-Ingelheim and Galecto, and is an advisor or consultant for Astra-Zeneca, Galecto, GSK, MSD, Pliant Therapeutics, Ambys Medicines, Mediar Therapeutics and Q32 Bio.Footnotes* https://figshare.com/articles/media/Multimodal_decoding_of_human_liver_regeneration/22100333...

Alternative Titles

Full title

Multimodal decoding of human liver regeneration

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2779803111

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2779803111

Other Identifiers

E-ISSN

2692-8205

DOI

10.1101/2023.02.24.529873